Journal of Neuro-Oncology

, Volume 92, Issue 2, pp 149–155

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

Authors

    • Division of Neuro-Oncology, Department of NeurologyBrigham and Women’s Hospital
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
    • Harvard Medical School
  • Jan Drappatz
    • Division of Neuro-Oncology, Department of NeurologyBrigham and Women’s Hospital
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
    • Harvard Medical School
  • Alona Muzikansky
    • Massachusetts General Hospital Biostatistics Center
  • Karly David
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
  • Mary Gerard
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
  • M. Brenna McNamara
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
  • Phuong Phan
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
  • Ainsley Ross
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
  • Santosh Kesari
    • Division of Neuro-Oncology, Department of NeurologyBrigham and Women’s Hospital
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
    • Harvard Medical School
  • Patrick Y. Wen
    • Division of Neuro-Oncology, Department of NeurologyBrigham and Women’s Hospital
    • Center for Neuro-Oncology, Dana-Farber Cancer Institute
    • Harvard Medical School
Clinical Study - Patient Study

DOI: 10.1007/s11060-008-9745-8

Cite this article as:
Norden, A.D., Drappatz, J., Muzikansky, A. et al. J Neurooncol (2009) 92: 149. doi:10.1007/s11060-008-9745-8

Abstract

Recent clinical trial results suggest that anti-angiogenic therapy may be effective against recurrent malignant glioma. Though these treatments prolong progression-free survival, the extent to which they prolong overall survival is unknown. We pooled data from 34 patients treated at a single institution on phase II clinical trials of bevacizumab and cediranib, and we compared these data to 18 patients treated on clinical trials of cytotoxic chemotherapies. In univariate and multivariate analyses, treatment group was a significant predictor of progression-free but not overall survival. Median progression-free survival was 8 vs. 22 weeks in patients treated with cytotoxic as compared to anti-angiogenic therapy (P = 0.01). Median overall survival was nearly identical in the two groups (39 vs. 37 weeks). The results of this exploratory analysis suggest that anti-angiogenic therapy may fail to prolong overall survival in patients with recurrent malignant glioma. If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies.

Keywords

Malignant gliomaAnti-angiogenic therapyProgression-free survival

Copyright information

© Springer Science+Business Media, LLC. 2008